Patents Assigned to Incyte Corporation
  • Solid forms of an HPK1 inhibitor
    Patent number: 11066394
    Abstract: The present invention relates to salt forms of the hematopoietic progenitor kinase 1 (HPK 1) inhibitors N-(2-((2S,4S)-4-Amino-2-(hydroxymethyl)pyrrolidin-1-yl)-5-fluorophenyl)-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide and N-(2-((2S,4S)-4-Amino-2-(hydroxymethyl)pyrrolidin-1-yl)-4-(4-cyanopyridin-3-yl)phenyl)-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide, including methods of preparation thereof, where the compounds are useful in the treatment of HPK1 mediated diseases such as cancer.
    Type: Grant
    Filed: August 5, 2020
    Date of Patent: July 20, 2021
    Assignee: Incyte Corporation
    Inventors: Zhongjiang Jia, William Frietze
  • Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
    Patent number: 11066404
    Abstract: The present application provides dihydropyrido[2,3-d]pyrimidone inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
    Type: Grant
    Filed: October 10, 2019
    Date of Patent: July 20, 2021
    Assignee: Incyte Corporation
    Inventors: Alexander Sokolsky, Liangxing Wu, Wenqing Yao
  • Salts of a Pim kinase inhibitor
    Patent number: 11066387
    Abstract: The present invention relates to salt forms of the Pim kinase inhibitor N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide, including methods of preparation thereof, and intermediates in the preparation thereof, where the compound is useful in the treatment of Pim kinase-related diseases such as cancer.
    Type: Grant
    Filed: May 21, 2019
    Date of Patent: July 20, 2021
    Assignee: Incyte Corporation
    Inventors: Zhongjiang Jia, Qun Li
  • 1H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c]pyridin-7(6H)-ones as inhibitors of BET proteins
    Patent number: 11059821
    Abstract: The present invention relates to substituted pyrrolopyridinones and substituted pyrazolopyridinones which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: August 14, 2020
    Date of Patent: July 13, 2021
    Assignee: Incyte Corporation
    Inventors: Andrew P. Combs, Thomas P. Maduskuie, Jr., Nikoo Falahatpisheh
  • Heterocyclic compounds useful as Pim kinase inhibitors
    Patent number: 11053215
    Abstract: The present application is concerned with heterocyclic compounds that inhibit the activity of Pim kinases and are useful in the treatment of diseases related to the activity of Pim kinases including, e.g., cancers and other diseases.
    Type: Grant
    Filed: September 9, 2019
    Date of Patent: July 6, 2021
    Assignee: Incyte Corporation
    Inventors: Oleg Vechorkin, Yun-Long Li, Alexander Sokolsky, Anlai Wang, Wenyu Zhu, Jincong Zhuo
  • Substituted tricyclic compounds as FGFR inhibitors
    Patent number: 11053246
    Abstract: The present invention relates to tricyclic compounds, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.
    Type: Grant
    Filed: April 7, 2020
    Date of Patent: July 6, 2021
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Liangxing Wu, Colin Zhang, Chunhong He, Liang Lu, Wenqing Yao
  • Aminopyrazine derivatives as PI3K-? inhibitors
    Patent number: 11046658
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-? which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Grant
    Filed: July 1, 2019
    Date of Patent: June 29, 2021
    Assignee: Incyte Corporation
    Inventors: Brent Douty, Yanran Ai, David M. Burns, Andrew P. Combs, Nikoo Falahatpisheh, Daniel Levy, Padmaja Polam, Lixin Shao, Stacey Shepard, Artem Shvartsbart, Eddy W. Yue, Andrew W. Buesking
  • Sustained release dosage forms for a JAK1 inhibitor
    Patent number: 11045421
    Abstract: This invention relates to sustained release dosage forms comprising {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharmaceutically acceptable salt thereof, and doses and methods related thereto.
    Type: Grant
    Filed: January 17, 2020
    Date of Patent: June 29, 2021
    Assignee: Incyte Corporation
    Inventors: Krishnaswamy Yeleswaram, Bhavnish Parikh, Dilip P. Modi, Trupti Sheth
  • Bicyclic heterocycles as FGFR4 inhibitors
    Patent number: 11014923
    Abstract: The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR4 enzyme and are useful in the treatment of FGFR4-associated diseases such as cancer.
    Type: Grant
    Filed: July 9, 2020
    Date of Patent: May 25, 2021
    Assignee: Incyte Corporation
    Inventors: Liang Lu, Liangxing Wu, Ding-Quan Qian, Wenqing Yao
  • Pyrazolopyrimidine compounds and uses thereof
    Patent number: 11014929
    Abstract: Disclosed are compounds of Formula (I): or a pharmaceutically acceptable salt thereof. Also provided are methods of using the compounds of Formula (I) for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.
    Type: Grant
    Filed: October 3, 2019
    Date of Patent: May 25, 2021
    Assignee: Incyte Corporation
    Inventors: Oleg Vechorkin, Kai Liu, Jun Pan, Alexander Sokolsky, Hai Fen Ye, Qinda Ye, Wenqing Yao, Joshua Hummel
  • Tricyclic heteroaryl compounds as STING activators
    Patent number: 11008344
    Abstract: The present application provides tricyclic heteroaryl compounds that activate the STING pathway to produce interferons, which are useful in the treatment of various diseases including infectious diseases and cancer.
    Type: Grant
    Filed: July 31, 2019
    Date of Patent: May 18, 2021
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Yingda Ye, Wenqing Yao
  • Bipyrazole derivatives as JAK inhibitors
    Patent number: 11001571
    Abstract: The present invention provides compounds of Formula I: or pharmaceutically acceptable salts thereof, as well as their compositions and methods of use, that inhibit the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
    Type: Grant
    Filed: August 29, 2019
    Date of Patent: May 11, 2021
    Assignee: Incyte Corporation
    Inventors: Yun-Long Li, Jincong Zhuo, Ding-Quan Qian, Song Mei, Ganfeng Cao, Yongchun Pan, Qun Li, Zhongjiang Jia
  • Advanced gaming visualization system
    Patent number: 10974134
    Abstract: A monocular unit permits visualization of image data received from an imaging device associated with a mobile computing device. The image data is displayed on a display of the mobile computing device. A trigger unit indicates a trigger actuation, where the trigger unit includes a trigger and a trigger bar, and where the trigger bar is moved by actuation of the trigger. A mounting component mounts the mobile computing device in relation to the monocular unit and the trigger unit. Adjustment wheels permit adjustment of the position of the mobile computing device in relation to the monocular unit, the trigger unit, and the mounting component.
    Type: Grant
    Filed: June 12, 2019
    Date of Patent: April 13, 2021
    Assignee: Incyte Corporation
    Inventor: Ivan Arbouzov
  • Process for preparing a composition comprising an enantiomeric excess of greater than or equal to 90% of the (R)-enantiomer of a compound of formula III
    Patent number: 10975085
    Abstract: The present invention is related to processes for preparing a composition comprising (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile, and related synthetic intermediate compounds. This compound is useful as an inhibitor of the Janus Kinase family of protein tyrosine kinases (JAKs) for treatment of inflammatory diseases, myeloproliferative disorders, and other diseases.
    Type: Grant
    Filed: June 10, 2019
    Date of Patent: April 13, 2021
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: Jiacheng Zhou, James D. Rodgers, Haisheng Wang
  • Imidazo[2,1-f][1,2,4]triazine compounds as pi3k-y inhibitors
    Patent number: 10975088
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which are inhibitors of PI3K-? which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Grant
    Filed: October 2, 2019
    Date of Patent: April 13, 2021
    Assignee: Incyte Corporation
    Inventors: Andrew W. Buesking, Richard B. Sparks, Andrew P. Combs, Brent Douty, Nikoo Falahatpisheh, Lixin Shao, Stacey Shepard, Eddy W. Yue, Artem Shvartsbart, David M. Burns, Daniel Levy
  • Salts of an LSD1 inhibitor and processes for preparing the same
    Patent number: 10968200
    Abstract: The present invention relates to processes and intermediates for preparing 3-(cyanomethyl)-3-(4-{[(1R,2S)-2-phenylcyclopropyl]amino}piperidin-1-yl)azetidine-1-sulfonamide, and salts and solid forms thereof, which selectively modulate demethylase. Particular embodiments contemplate compounds and disease indications amenable to treatment by modulation of lysine specific demethylase-1 (LSD1).
    Type: Grant
    Filed: August 29, 2019
    Date of Patent: April 6, 2021
    Assignee: Incyte Corporation
    Inventors: Zhongjiang Jia, Wayne Han, Yongchun Pan, Timothy Martin, Jiacheng Zhou, Qun Li
  • Substituted [1,2,4]triazolo[1,5-a]pyrazines as LSD1 inhibitors
    Patent number: 10968221
    Abstract: The present invention is directed to [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-a]pyrazine derivatives of Formula IIa, or a pharmaceutically acceptable salt thereof, which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: October 3, 2019
    Date of Patent: April 6, 2021
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Xiaozhao Wang, Wenqing Yao, Colin Zhang
  • Bicyclic heterocycles as FGFR inhibitors
    Patent number: 10947230
    Abstract: The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.
    Type: Grant
    Filed: September 10, 2019
    Date of Patent: March 16, 2021
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Yaping Sun, Wenqing Yao, Liangxing Wu, Meizhong Xu, Ding-Quan Qian, Fenglei Zhang
  • Tricyclic heterocyclic compounds as sting activators
    Patent number: 10947227
    Abstract: The present application provides tricyclic heterocyclic compounds that activate the STING pathway to produce interferons, which are useful in the treatment of various diseases including infectious diseases and cancer.
    Type: Grant
    Filed: May 24, 2019
    Date of Patent: March 16, 2021
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Neil Lajkiewicz, Yingda Ye, Zhenwu Li, Wenqing Yao
  • Pyrazolopyridine compounds and uses thereof
    Patent number: 10934288
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.
    Type: Grant
    Filed: August 20, 2019
    Date of Patent: March 2, 2021
    Assignee: Incyte Corporation
    Inventors: Oleg Vechorkin, Kai Liu, Alexander Sokolsky, Anlai Wang, Hai Fen Ye, Qinda Ye, Wenqing Yao